Jane Street Group, LLC Cardiff Oncology, Inc. Call Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$2.31 - $5.35 $115,269 - $266,965	49,900 New	49,900 $216,000
Q2 2022 Aug 16, 2022	SELL	$1.17 - $2.61 $14,157 - $31,581	-12,100 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$2.11 - $7.25 $28,907 - $99,325	-13,700 Reduced 53.1%	12,100 $30,000
Q4 2021 Feb 15, 2022	SELL	$5.18 - $7.24 $300,440 - $419,920	-58,000 Reduced 69.21%	25,800 $155,000
Q3 2021 Nov 16, 2021	BUY	$5.01 - $7.58 $92,184 - $139,472	18,400 Added 28.13%	83,800 $558,000
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $94,430 - $142,568	-14,200 Reduced 17.84%	65,400 $435,000
Q1 2021 May 18, 2021	SELL	$9.1 - $19.57 $3,640 - $7,828	-400 Reduced 0.5%	79,600 $737,000
Q4 2020 Feb 17, 2021	BUY	$12.02 - $24.71 $51,686 - $106,253	4,300 Added 5.68%	80,000 $1.44 Million
Q3 2020 Nov 17, 2020	BUY	$4.25 - $14.19 $321,725 - $1.07 Million	75,700 New	75,700 $1.07 Million

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $175M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.